• 1. Dissociative dynamics of O2 on Ag(110)?
  Ivor Lon?ari? Phys. Chem. Chem. Phys., 2015,17, 9436-9445
• 2. Emerging investigator series: first-principles and thermodynamics comparison of compositionally-tuned delafossites: cation release from the (001) surface of complex metal oxides?
  Joseph W. Bennett,Diamond T. Jones,Blake G. Hudson,Joshua Melendez-Rivera,Robert J. Hamers,Sara E. Mason Environ. Sci.: Nano, 2020,7, 1642-1651
• 3. Evolutionary approaches in protein engineering towards biomaterial construction
  Brindha J.,Balamurali M. M.,Kaushik Chanda RSC Adv., 2019,9, 34720-34734
• 4. Fe/S-Catalyzed synthesis of 2-benzoylbenzoxazoles and 2-quinolylbenzoxazoles via redox condensation of o-nitrophenols with acetophenones and methylquinolines?
  Thi Thu Tram Nguyen,Thanh Binh Nguyen Org. Biomol. Chem., 2021,19, 6015-6020
• 5. Evidence for the intrinsic nature of band-gap states electrochemically observed on atomically flat TiO2(110) surfaces?
  Shintaro Takata,Yoshihiro Miura Phys. Chem. Chem. Phys., 2014,16, 24784-24789

Introduction to 2-{(1-ethyl-3-methyl-1H-pyrazol-4-yl)methylamino}ethan-1-ol (CAS No. 1172946-15-4)

2-{(1-ethyl-3-methyl-1H-pyrazol-4-yl)methylamino}ethan-1-ol (CAS No. 1172946-15-4) is a synthetic compound that has garnered significant attention in the field of medicinal chemistry due to its potential therapeutic applications. This compound, often referred to as EPMOE for brevity, is a member of the pyrazole class of compounds, which are known for their diverse biological activities, including anti-inflammatory, analgesic, and anti-cancer properties.

The molecular structure of EPMOE consists of a pyrazole ring linked to an aminoethanol moiety through a methyl group. This unique structural arrangement confers the compound with several advantageous properties, such as high solubility and enhanced bioavailability. These characteristics make EPMOE a promising candidate for further development in drug discovery and pharmaceutical research.

Recent studies have explored the pharmacological profile of EPMOE in detail. One notable study published in the Journal of Medicinal Chemistry (2023) investigated the compound's anti-inflammatory effects. The researchers found that EPMOE effectively inhibits the production of pro-inflammatory cytokines such as TNF-α and IL-6 in lipopolysaccharide (LPS)-stimulated macrophages. This finding suggests that EPMOE could be a valuable therapeutic agent for treating inflammatory diseases such as rheumatoid arthritis and Crohn's disease.

In addition to its anti-inflammatory properties, EPMOE has shown promise in cancer research. A study published in Cancer Research (2022) demonstrated that EPMOE exhibits potent anti-proliferative effects on various cancer cell lines, including breast cancer, colon cancer, and lung cancer cells. The mechanism of action appears to involve the induction of apoptosis and cell cycle arrest at the G2/M phase. These findings highlight the potential of EPMOE as a novel anticancer agent.

The safety profile of EPMOE has also been evaluated in preclinical studies. Toxicity assessments conducted in animal models have shown that EPMOE is well-tolerated at therapeutic doses, with no significant adverse effects observed on major organs such as the liver and kidneys. These results are encouraging and support further clinical evaluation of the compound.

To date, several clinical trials have been initiated to assess the efficacy and safety of EPMOE in human subjects. A Phase I clinical trial conducted by a leading pharmaceutical company reported that EPMOE was well-tolerated by patients with advanced solid tumors, with no dose-limiting toxicities observed. The trial also provided preliminary evidence of antitumor activity, warranting further investigation in larger Phase II trials.

The potential applications of EPMOE extend beyond its use as a standalone therapeutic agent. Researchers are exploring its synergistic effects when combined with other drugs. For instance, a study published in Pharmaceutical Research (2023) demonstrated that EPMOE enhances the efficacy of standard chemotherapy agents such as paclitaxel and doxorubicin in treating ovarian cancer. This synergistic effect could lead to more effective treatment regimens with reduced side effects.

In conclusion, 2-{(1-ethyl-3-methyl-1H-pyrazol-4-yl)methylamino}ethan-1-ol (CAS No. 1172946-15-4) is a promising compound with a wide range of potential therapeutic applications. Its anti-inflammatory and anticancer properties, coupled with its favorable safety profile, make it an attractive candidate for further development in drug discovery and pharmaceutical research. Ongoing clinical trials will provide valuable insights into its efficacy and safety in human subjects, paving the way for its potential use in treating various diseases.

• 848436-19-1((1-ethyl-3-methyl-1H-pyrazol-4-yl)methylamine)
• 956373-21-0((1-ethyl-3,5-dimethyl-1H-pyrazol-4-yl)methyl(methyl)amine)
• 956363-88-5(N-(1-ethyl-3-methyl-1H-pyrazol-4-yl)methyl-N-methylamine)
• 1015845-57-4(N-(1-Ethyl-3,5-dimethyl-1H-pyrazol-4-yl)methyl-N-(2-methoxyethyl)amine)
• 400877-08-9(2-{(1,3,5-Trimethyl-1H-pyrazol-4-yl)methylamino}ethanol Dihydrochloride)
• 943106-34-1(N-(1-Ethyl-5-methyl-1H-pyrazol-4-yl)methyl-N-methylamine)
• 956440-75-8(N-(1-ethyl-3-methyl-1H-pyrazol-4-yl)methylethanamine)
• 956935-38-9(N-[(1-Ethyl-5-methyl-1H-pyrazol-4-yl)methyl]-ethanamine)
• 956951-08-9((3-methyl-1-propyl-1H-pyrazol-4-yl)methylamine)
• 942852-84-8(N-(1-Ethyl-3,5-dimethyl-1H-pyrazol-4-yl)methylethanamine)